Composition of Certain Financial Statement Captions - Changes in Goodwill (Details) - USD ($) $ in Thousands	3 Months Ended
Mar. 31, 2022	Jan. 01, 2022	Dec. 31, 2021
Goodwill [Roll Forward]
Goodwill, beginning balance	$ 519,052	$ 710,408	$ 520,601
Cumulative impairment at January 1			(38,023)
Foreign exchange and other	(153,333)
Goodwill, ending balance	519,052	710,408	520,601
BioReference
Goodwill [Roll Forward]
Goodwill, beginning balance	283,000
Goodwill, ending balance	283,000
Pharmaceutical \| CURNA
Goodwill [Roll Forward]
Goodwill, beginning balance	0	4,827
Cumulative impairment at January 1			(4,827)
Foreign exchange and other	0
Goodwill, ending balance	0	4,827
Pharmaceutical \| Rayaldee
Goodwill [Roll Forward]
Goodwill, beginning balance	84,853	86,554
Cumulative impairment at January 1			0
Foreign exchange and other	(1,701)
Goodwill, ending balance	84,853	86,554
Pharmaceutical \| FineTech
Goodwill [Roll Forward]
Goodwill, beginning balance	0	11,698
Cumulative impairment at January 1			(11,698)
Foreign exchange and other	0
Goodwill, ending balance	0	11,698
Pharmaceutical \| OPKO Biologics
Goodwill [Roll Forward]
Goodwill, beginning balance	139,784	139,784
Cumulative impairment at January 1			0
Foreign exchange and other	0
Goodwill, ending balance	139,784	139,784
Pharmaceutical \| OPKO Chile
Goodwill [Roll Forward]
Goodwill, beginning balance	4,062	3,760
Cumulative impairment at January 1			0
Foreign exchange and other	302
Goodwill, ending balance	4,062	3,760
Pharmaceutical \| OPKO Health Europe
Goodwill [Roll Forward]
Goodwill, beginning balance	7,328	7,478
Cumulative impairment at January 1			0
Foreign exchange and other	(150)
Goodwill, ending balance	7,328	7,478
Pharmaceutical \| OPKO Mexico
Goodwill [Roll Forward]
Goodwill, beginning balance	0	100
Cumulative impairment at January 1			(100)
Foreign exchange and other	0
Goodwill, ending balance	0	100
Pharmaceutical \| Transition Therapeutics
Goodwill [Roll Forward]
Goodwill, beginning balance	0	3,421
Cumulative impairment at January 1			(3,421)
Foreign exchange and other	0
Goodwill, ending balance	0	3,421
Diagnostics \| BioReference
Goodwill [Roll Forward]
Goodwill, beginning balance	283,025	434,809
Cumulative impairment at January 1			0
Foreign exchange and other	(151,784)
Goodwill, ending balance	283,025	434,809
Diagnostics \| OPKO Diagnostics
Goodwill [Roll Forward]
Goodwill, beginning balance	0	17,977
Cumulative impairment at January 1			$ (17,977)
Foreign exchange and other	0
Goodwill, ending balance	$ 0	$ 17,977

Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(10)(1))
-URI http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 45
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 852
-SubTopic 10
-Section 55
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266

+ Details

Name:	us-gaap_Goodwill
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Amount of foreign currency translation gain (loss) which increases (decreases) an asset representing future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267

+ Details

Name:	us-gaap_GoodwillForeignCurrencyTranslationGainLoss
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Amount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (h)
-URI http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267

+ Details

Name:	us-gaap_GoodwillImpairedAccumulatedImpairmentLoss
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.

+ References

No definition available.

+ Details

Name:	us-gaap_GoodwillRollForward
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Details

Name:	us-gaap_BusinessAcquisitionAxis=opk_BioReferenceMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_StatementBusinessSegmentsAxis=opk_PharmaceuticalMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_BusinessAcquisitionAxis=opk_CURNAMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_BusinessAcquisitionAxis=opk_EirGenPharmaLimitedMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_BusinessAcquisitionAxis=opk_FineTechMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_BusinessAcquisitionAxis=opk_OPKOBiologicsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_BusinessAcquisitionAxis=opk_OpkoChileMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_BusinessAcquisitionAxis=opk_OPKOHealthEuropeMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_BusinessAcquisitionAxis=opk_OPKOMexicoMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_BusinessAcquisitionAxis=opk_TransitionTherapeuticsInc.Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_StatementBusinessSegmentsAxis=opk_DiagnosticsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_BusinessAcquisitionAxis=opk_OpkoDiagnosticsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: